(10) Patent No.: US 9315567 B2

Total Page:16

File Type:pdf, Size:1020Kb

(10) Patent No.: US 9315567 B2 US009315567B2 (12) United States Patent (10) Patent No.: US 9,315,567 B2 Chang et al. (45) Date of Patent: *Apr. 19, 2016 (54) T-CELL REDIRECTING BISPECIFIC I6/2842 (2013.01); C07K 16/2845 (2013.01); ANTIBODES FORTREATMENT OF C07K 16/2851 (2013.01); C07K 16/2863 DISEASE (2013.01); C07K 16/2866 (2013.01); C07K 16/2875 (2013.01); C07K 16/2878 (2013.01); (71) Applicant: IBC Pharmaceuticals, Inc., Morris C07K 16/2884 (2013.01); C07K 16/2887 Plains, NJ (US) (2013.01); C07K 16/2893 (2013.01); C07K (72) Inventors: Chien-Hsing Chang, Downingtown, PA I6/2896 (2013.01); C07K 16/30 (2013.01); (US); David M. Goldenberg, Mendham, C07K 16/3007 (2013.01); C07K 16/32 NJ (US); Edmund A. Rossi, Woodland (2013.01); C07K 16/40 (2013.01); C07K 16/44 Park, NJ (US); Diane Rossi, Woodland (2013.01); A61K 2039/505 (2013.01); C07K Park, NJ (US) 2317/31 (2013.01); C07K 2317/54 (2013.01); C07K 231 7/55 (2013.01); C07K 2317/622 (73) Assignee: IBC Pharmaceuticals, Inc., Morris (2013.01); C07K 2317/73 (2013.01) Plains, NJ (US) (58) Field of Classification Search CPC ........ C07K 16/46; C07K 16/30; C07K 16/28; (*) Notice: Subject to any disclaimer, the term of this C07K 16/2809; C07K 2317/31: C07K patent is extended or adjusted under 35 2317/622; C07K 2317/54; C07K 2317/55; U.S.C. 154(b) by 0 days. C07K 2317/73; A61K 2317/00; A61K38/212: This patent is Subject to a terminal dis A61K2039/505; A61K 39/39958 claimer. See application file for complete search history. (21) Appl. No.: 13/966,450 (56) References Cited (22) Filed: Aug. 14, 2013 U.S. PATENT DOCUMENTS Prior Publication Data 4,046,722 A 9, 1977 Rowland (65) 4,699,784. A 10, 1987 Shih et al. US 2014/0050660 A1 Feb. 20, 2014 (Continued) Related U.S. Application Data FOREIGN PATENT DOCUMENTS (60) Provisional application No. 61/682.965, filed on Aug. WO 99.54440 10, 1999 14, 2012, provisional application No. 61/733,268, WO 00,068248 11, 2000 filed on Dec. 4, 2012, provisional application No. (Continued) 61/807,998, filed on Apr. 3, 2013. OTHER PUBLICATIONS (51) Int. C. Yu et al., Investigative Ophthalmology & Visual Science 49(2): 522 C07K I6/46 (2006.01) 527, Feb. 2008.* C07K 6/28 (2006.01) C07K 6/30 (2006.01) (Continued) A6 IK38/2I (2006.01) A 6LX39/395 (2006.01) Primary Examiner — Phuong Huynh C07K I6/44 (2006.01) (74) Attorney, Agent, or Firm — Richard A. Nakashima C07K 6/8 (2006.01) A6 IK 47/42 (2006.01) (57) ABSTRACT A6 IK 45/06 (2006.01) A6 IK38/9 (2006.01) The present invention concerns compositions and methods of C07K 6/40 (2006.01) use of T-cell redirecting complexes, with at least one binding C07K 16/32 (2006.01) site for a T-cell antigen and at least one binding site for an A61 K39/00 (2006.01) antigen on a diseased cell or pathogen. Preferably, the com (52) U.S. C. plex is a DNLTM complex. More preferably, the complex CPC ............... C07K 16/18 (2013.01); A61K 38/195 comprises a bispecific antibody (bSAb). Most preferably, the (2013.01); A61 K38/21 (2013.01); A61 K bSAb is an anti-CD3xanti-CD19 bispecific antibody, 38/212 (2013.01); A61 K38/215 (2013.01); although antibodies against other T-cell antigens and/or dis A61K38/217 (2013.01); A61K.39/395 ease-associated antigens may be used. The complex is (2013.01); A61 K39/39558 (2013.01); A61 K capable of targeting effector T cells to induce T-cell-mediated 45/06 (2013.01); A61 K47/42 (2013.01); C07K cytotoxicity of cells associated with a disease. Such as cancer, I6/283 (2013.01); C07K 16/2803 (2013.01); autoimmune disease or infectious disease. The cytotoxic C07K 16/2806 (2013.01); C07K 16/2809 immune response is enhanced by co-administration of inter (2013.01); C07K 16/289 (2013.01); C07K feron-based agents that comprise interferon-C. interferon-B, I6/281.2 (2013.01); C07K 16/2815 (2013.01); interferon-W1, interferon-M2 or interferon-M3. C07K 16/2818 (2013.01); C07K 16/2827 (2013.01); C07K 16/2833 (2013.01); C07K 10 Claims, 20 Drawing Sheets US 9,315,567 B2 Page 2 (56) References Cited Golay et al., Archives of Biochemistry and Biophysics 526: 146-153, 2012.* U.S. PATENT DOCUMENTS Davis et al., Clinical Cancer Research 6: 2644-2652, Jul. 2000. Kontermann et al., Acta Pharmacologics Sinica 26(1): 1-9, Jan. 4,868,109 A 9/1989 Lansdorp et al. 2005.* 5,770,198 A 6, 1998 Coller et al. Greiner et al., Cancer Res 44:3208-3214, Aug. 1984.* 5,871,945 A 2f1999 Lockerbie et al. Rossi et al., Bioconjugate Chemistry 24: 63-71, Jan. 16, 2013.* 6,261,537 B1 7/2001 Klaveness et al. 6,306,393 B1 10/2001 Goldenberg et al. Stancovski et al., PNAS, 88: 8691-8695, 1991.* 6,524,854 B1 2/2003 Monia et al. Baeuerle et al., Cancer Res 69 (12): 4941-4944, 2009.* 7,060,506 B2 6/2006 Craig Rossi, Mol Cancer Ther 13(10): 2341-51, 2014.* 7,238,785 B2 * 7/2007 Govindan et al. .......... 530,387.3 Cardillo et al., “Targeting both IGF-1R and mTOR synergistically 7,521,056 B2 4/2009 Chang et al. inhibits growth of renal cell carcinoma in vitro”. BMC Cancer. Apr. 7,527,787 B2 5/2009 Chang et al. 1, 2013:13:170. 7,534,866 B2 5/2009 Chang et al. Chang et al., “A new method to produce monoPEGylated dimeric 7.550,143 B2 6/2009 Chang et al. cytokines shown with human interferon-C2b. Bioconjug Chem. 7,666.400 B2 2/2010 Chang et al. Oct. 21, 2009:20(10): 1899-907. 7,858,070 B2 12/2010 Chang et al. Chang et al., “A novel class of anti-HIV agents with multiple copies 7,871,622 B2 1/2011 Chang et al. 7,901,680 B2 3/2011 Chang et al. of enfuvirtide enhances inhibition of viral replication and cellular 7,906,121 B2 3/2011 Chang et al. transmission in vitro”. PLoS One. 2012;7(7):e4 1235. 7,981,398 B2 7/2011 Chang et al. Changet al., “Evaluation of a novel hexavalent humanized anti-IFG 8,003,111 B2 8/2011 Chang et al. 1 Rantibody and its bivalent parental IgG in diverse cancer cell lines', 8,034.352 B2 10/2011 Chang et al. PLoS One. 2012;7(8):e44235. 8, 158,129 B2 4/2012 Chang et al. Goldenberg et al., “Cancer Imaging and Therapy with Bispecific 8,163,291 B2 4/2012 Chang et al. Antibody Pretargeting. Update Cancer Ther. Mar. 2007:2(1):19-31. 8,211,440 B2 7/2012 Chang et al. Govindan et al., “Designing immunoconjugates for cancer therapy'. 8,246,960 B2 8/2012 Chang et al. Expert Opin Biol Ther. Jul. 2012; 12(7):873-90. 8,277,817 B2 10/2012 Chang et al. Liu et al., “Trop-2-targeting tetrakis-ranpirinase has potent antitumor 8,282,934 B2 10/2012 Chang et al. activity against triple-negative breast cancer'. Mol Cancer. Mar. 10, 8,349,332 B2 1/2013 Chang et al. 8.435,540 B2 5/2013 Chang et al. 2014:13:53. 8,475,794 B2 7/2013 Chang et al. Rossi et al., "Hexavalent bispecific antibodies represent a new class 8,481,041 B2 7/2013 Chang et al. of anticancer therapeutics: 1. Properties of anti-CD20/CD22 antibod 8,491.914 B2 7/2013 Chang et al. ies in lymphoma'. Blood. Jun. 11, 2009; 113(24):6161-71. 8,551480 B2 10/2013 Chang et al. Rossi et al., “CD20-targeted tetrameric interferon-alpha, a novel and 8,562.988 B2 10/2013 Chang et al. potent immunocytokine for the therapy of B-cell lymphomas'. 8,597.659 B2 12/2013 Chang et al. Blood. Oct. 29, 2009; 114(18):3864-71. 2003. O198956 A1 10/2003 Makowski et al. Rossi et al., “The dock-and-lock method combines recombinant 2003/0232420 A1 12/2003 Braun et al. engineering with site-specific covalent conjugation to generate 2004, OO18587 A1 1/2004 Makowski et al. multifunctional structures'. Bioconjug Chem. Mar. 21. 2004/O126361 A1 7/2004 Saifer et al. 2005, OOO3403 A1 1/2005 Rossi et al. 2012:23(3):309-23. 2005/0153923 A1* 7/2005 Kinch ............................. 514,44 Rossi et al., “Complex and defined biostructures with the dock-and 2006/0210475 A1 9/2006 Goldenberg et al. lock method”. Trends Pharmacol Sci. Sep. 2012:33(9):474-81. 2007/0264265 A1 1 1/2007 Goldenberg et al. Rossiet al., “A new class of bispecificantibodies to redirect T cells for 2007/0274998 A1 11, 2007 Utku cancer immunotherapy”, MAbs. Mar.-Apr. 2014;6(2):381-91. 2009/0111143 A1 4/2009 Goldenberg et al. Sharkey et al., “Improved cancer therapy and molecular imaging with 2011/0020273 A1 1/2011 Chang et al. multivalent, multispecific antibodies', Cancer Biother Radiopharm. 2011 OO64754 A1 3/2011 Taylor et al. Feb. 2010:25(1):1-12. 2011/O143417 A1 6/2011 Chang et al. Abbas et al., Cellular and Molecular Immunology, W.B. Saunders 2011/O158905 A1 6/2011 Goldenberg et al. Comp. 1991, p. 43. 2011/O189083 A1 8/2011 Chang et al. Alto et al., “Bioinformatic design of A-kinase anchoring protein-in 2012fOO93769 A1 4/2012 Chang et al.
Recommended publications
  • Predictive QSAR Tools to Aid in Early Process Development of Monoclonal Antibodies
    Predictive QSAR tools to aid in early process development of monoclonal antibodies John Micael Andreas Karlberg Published work submitted to Newcastle University for the degree of Doctor of Philosophy in the School of Engineering November 2019 Abstract Monoclonal antibodies (mAbs) have become one of the fastest growing markets for diagnostic and therapeutic treatments over the last 30 years with a global sales revenue around $89 billion reported in 2017. A popular framework widely used in pharmaceutical industries for designing manufacturing processes for mAbs is Quality by Design (QbD) due to providing a structured and systematic approach in investigation and screening process parameters that might influence the product quality. However, due to the large number of product quality attributes (CQAs) and process parameters that exist in an mAb process platform, extensive investigation is needed to characterise their impact on the product quality which makes the process development costly and time consuming. There is thus an urgent need for methods and tools that can be used for early risk-based selection of critical product properties and process factors to reduce the number of potential factors that have to be investigated, thereby aiding in speeding up the process development and reduce costs. In this study, a framework for predictive model development based on Quantitative Structure- Activity Relationship (QSAR) modelling was developed to link structural features and properties of mAbs to Hydrophobic Interaction Chromatography (HIC) retention times and expressed mAb yield from HEK cells. Model development was based on a structured approach for incremental model refinement and evaluation that aided in increasing model performance until becoming acceptable in accordance to the OECD guidelines for QSAR models.
    [Show full text]
  • WO 2015/028850 Al 5 March 2015 (05.03.2015) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2015/028850 Al 5 March 2015 (05.03.2015) P O P C T (51) International Patent Classification: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, C07D 519/00 (2006.01) A61P 39/00 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, C07D 487/04 (2006.01) A61P 35/00 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, A61K 31/5517 (2006.01) A61P 37/00 (2006.01) HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, A61K 47/48 (2006.01) KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (21) International Application Number: OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, PCT/IB2013/058229 SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, (22) International Filing Date: TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, 2 September 2013 (02.09.2013) ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (26) Publication Language: English GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, (71) Applicant: HANGZHOU DAC BIOTECH CO., LTD UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, [US/CN]; Room B2001-B2019, Building 2, No 452 Sixth TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, Street, Hangzhou Economy Development Area, Hangzhou EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, City, Zhejiang 310018 (CN).
    [Show full text]
  • Tanibirumab (CUI C3490677) Add to Cart
    5/17/2018 NCI Metathesaurus Contains Exact Match Begins With Name Code Property Relationship Source ALL Advanced Search NCIm Version: 201706 Version 2.8 (using LexEVS 6.5) Home | NCIt Hierarchy | Sources | Help Suggest changes to this concept Tanibirumab (CUI C3490677) Add to Cart Table of Contents Terms & Properties Synonym Details Relationships By Source Terms & Properties Concept Unique Identifier (CUI): C3490677 NCI Thesaurus Code: C102877 (see NCI Thesaurus info) Semantic Type: Immunologic Factor Semantic Type: Amino Acid, Peptide, or Protein Semantic Type: Pharmacologic Substance NCIt Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells, while VEGF is overexpressed in many tumors and is correlated to tumor progression. PDQ Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,658,773 B2 Zeng Et Al
    USOO8658.773B2 (12) United States Patent (10) Patent No.: US 8,658,773 B2 Zeng et al. (45) Date of Patent: Feb. 25, 2014 (54) ULTRAFILTRATION CONCENTRATION OF 7,635,473 B2 12/2009 Warne et al. ALLOTYPE SELECTED ANTIBODES FOR Z$59. R: $388 E. et f SMALL-VOLUMEADMINISTRATION 7,829,5254 B2 11/2010 FrevertaSC ( a. (75) Inventors: Li Zeng, Edison, NJ (US); Rohini 7,847,071 B2 12/2010 Bonnerjea et al. Mitra, Brigdewater, NJ (US); Edmund 2. R: 138. Sagital. A. Rossi, Woodland Park, NJ (US); 7.87622 B2 1/2011 Changet al. Hans J. Hansen, Picayune, MS (US); 7,901,680 B2 3/2011 Chang et al. David M. Goldenberg, Mendham, NJ 7,906,118 B2 3/2011 Chang et al. (US) 7,906,121 B2 3/2011 Chang et al. 7.919,087 B2 4/2011 Hansen et al. (73) Assignee: Immunomedics, Inc., Morris Plains, NJ 7.931,903 B2 4/2011 Hansen et al. (US) 2001/0014326 A1 8/2001 Andya et al. 2003,0004094 A1 1/2003 Ghose et al. (*) Notice: Subject to any disclaimer, the term of this 2004/0033228 A1 2/2004 Krause et al. patent is extended or adjusted under 35 2004/0033561 A1 2/2004 O'Keefe et al. U.S.C. 154(b) by 0 days. 2004/0208870 A1 10, 2004 Allan 2005.0053666 A1 3/2005 TZannis et al. (21) Appl. No.: 13/461,307 2005, 0118167 A1 6, 2005 Okada et al. 2006/0153846 A1* 7/2006 Krause et al. .............. 424,145.1 (22) Filed: May 1, 2012 2006, O193850 A1 8, 2006 Warne et al.
    [Show full text]
  • Looking for Therapeutic Antibodies in Next Generation Sequencing Repositories
    bioRxiv preprint doi: https://doi.org/10.1101/572958; this version posted March 10, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Title: Looking for Therapeutic Antibodies in Next Generation Sequencing Repositories. Authors: Konrad Krawczyk1*, Matthew Raybould2, Aleksandr Kovaltsuk2, Charlotte M. Deane2 1 NaturalAntibody, Hamburg, Germany 2 Oxford University Department of Statistics, Oxford, UK *Correspondence to [email protected] Abstract: Recently it has become possible to query the great diversity of natural antibody repertoires using Next Generation Sequencing (NGS). These methods are capable of producing millions of sequences in a single experiment. Here we compare Clinical Stage Therapeutic antibodies to the ~1b sequences from 60 independent sequencing studies in the Observed Antibody Space Database. Of the 242 post Phase I antibodies, we find 16 with sequence identity matches of 95% or better for both heavy and light chains. There are also 54 perfect matches to therapeutic CDR-H3 regions in the NGS outputs, suggesting a nontrivial amount of convergence between naturally observed sequences and those developed artificially. This has potential implications for both the discovery of antibody therapeutics and the legal protection of commercial antibodies. Introduction Antibodies are proteins in jawed vertebrates that recognize noxious molecules (antigens) for elimination. An organism expresses millions of diverse antibodies to increase the chances that some of them will be able to bind the foreign antigen, initiating the adaptive immune response.
    [Show full text]
  • The Two Tontti Tudiul Lui Hi Ha Unit
    THETWO TONTTI USTUDIUL 20170267753A1 LUI HI HA UNIT ( 19) United States (12 ) Patent Application Publication (10 ) Pub. No. : US 2017 /0267753 A1 Ehrenpreis (43 ) Pub . Date : Sep . 21 , 2017 ( 54 ) COMBINATION THERAPY FOR (52 ) U .S . CI. CO - ADMINISTRATION OF MONOCLONAL CPC .. .. CO7K 16 / 241 ( 2013 .01 ) ; A61K 39 / 3955 ANTIBODIES ( 2013 .01 ) ; A61K 31 /4706 ( 2013 .01 ) ; A61K 31 / 165 ( 2013 .01 ) ; CO7K 2317 /21 (2013 . 01 ) ; (71 ) Applicant: Eli D Ehrenpreis , Skokie , IL (US ) CO7K 2317/ 24 ( 2013. 01 ) ; A61K 2039/ 505 ( 2013 .01 ) (72 ) Inventor : Eli D Ehrenpreis, Skokie , IL (US ) (57 ) ABSTRACT Disclosed are methods for enhancing the efficacy of mono (21 ) Appl. No. : 15 /605 ,212 clonal antibody therapy , which entails co - administering a therapeutic monoclonal antibody , or a functional fragment (22 ) Filed : May 25 , 2017 thereof, and an effective amount of colchicine or hydroxy chloroquine , or a combination thereof, to a patient in need Related U . S . Application Data thereof . Also disclosed are methods of prolonging or increasing the time a monoclonal antibody remains in the (63 ) Continuation - in - part of application No . 14 / 947 , 193 , circulation of a patient, which entails co - administering a filed on Nov. 20 , 2015 . therapeutic monoclonal antibody , or a functional fragment ( 60 ) Provisional application No . 62/ 082, 682 , filed on Nov . of the monoclonal antibody , and an effective amount of 21 , 2014 . colchicine or hydroxychloroquine , or a combination thereof, to a patient in need thereof, wherein the time themonoclonal antibody remains in the circulation ( e . g . , blood serum ) of the Publication Classification patient is increased relative to the same regimen of admin (51 ) Int .
    [Show full text]
  • Patent Application Publication Oo) Pub. No.: US 2014/0099254 a L Chang Et Al
    US 20140099254A1 US 20140099254A1 (19) United States (12) Patent Application Publication oo) Pub. No.: US 2014/0099254 A l Chang et al. (43 ) Pub. Date: A pr. 10,2014 (54) COMBINATION THERAPY FOR INDUCING A 61K 4S/06 (2006.01) IMMUNE RESPONSE TO DISEASE A61K 39/395 (2006.01) (52) U.S. Cl. (71) Applicant: IBC Pharmaceuticals, Inc., Morris CPC A 6 1 K 38/212 (2013.01); A61K39/3955 Plains, NJ (US) (2013.01); A61K39/39558 (2013.01); A61K 47/48569 (2013.01); A61K47/4853 (2013.01); (72) Inventors: Chien-Hsing Chang, Downingtown, PA A 6 1 K 45/06 (2013.01) (US); David M. Goldenberg, Mendham, USPC ... 424/1.11; 424/85.7; 424/142.1; 424/136.1; NJ (US); Edmund A. Rossi, Woodland 424/85.6; 424/85.5; 424/85.2 Park, NJ (US); Diane Rossi, Woodland Park, NJ (US) (57) ABSTRACT (73) Assignee: IBC Pharmaceuticals, Inc., Morris Plains, NJ (US) The present invention concerns combinations of two or more (21) Appl. No.: 14/106,737 agents for inducing an immune response to cancer or infec­ tious disease. Agents may include leukocyte redirecting com­ (22) Filed: Dec. 14, 2013 plexes, antibody-drug conjugates, interferons (preferably Related U.S. Application Data interferon-α), and/or checkpoint inhibitor antibodies. The leukocyte redirecting complexes have at least one binding site (63) Continuation-in-part of application No. 13/966,450, for a leukocyte antigen and at least one binding site for an filed on Aug. 14, 2013. antigen on a diseased cell or pathogen. Preferably, the com­ (60) Provisional application No.
    [Show full text]
  • WO 2016/176089 Al 3 November 2016 (03.11.2016) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2016/176089 Al 3 November 2016 (03.11.2016) P O P C T (51) International Patent Classification: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, A01N 43/00 (2006.01) A61K 31/33 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (21) International Application Number: KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, PCT/US2016/028383 MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (22) International Filing Date: PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, 20 April 2016 (20.04.2016) SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of regional protection available): ARIPO (BW, GH, (30) Priority Data: GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, 62/154,426 29 April 2015 (29.04.2015) US TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, (71) Applicant: KARDIATONOS, INC. [US/US]; 4909 DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, Lapeer Road, Metamora, Michigan 48455 (US).
    [Show full text]
  • (INN) for Biological and Biotechnological Substances
    INN Working Document 05.179 Update 2013 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) INN Working Document 05.179 Distr.: GENERAL ENGLISH ONLY 2013 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) International Nonproprietary Names (INN) Programme Technologies Standards and Norms (TSN) Regulation of Medicines and other Health Technologies (RHT) Essential Medicines and Health Products (EMP) International Nonproprietary Names (INN) for biological and biotechnological substances (a review) © World Health Organization 2013 All rights reserved. Publications of the World Health Organization are available on the WHO web site (www.who.int ) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected] ). Requests for permission to reproduce or translate WHO publications – whether for sale or for non-commercial distribution – should be addressed to WHO Press through the WHO web site (http://www.who.int/about/licensing/copyright_form/en/index.html ). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned.
    [Show full text]
  • Phage Display Libraries: from Binders to Targeted Drug Delivery and Human Therapeutics
    Molecular Biotechnology (2019) 61:286–303 https://doi.org/10.1007/s12033-019-00156-8 REVIEW Phage Display Libraries: From Binders to Targeted Drug Delivery and Human Therapeutics Mouldy Sioud1 Published online: 7 February 2019 © Springer Science+Business Media, LLC, part of Springer Nature 2019 Abstract The application of repertoire selection technologies for the study and characterization of tumor heterogeneity is an area of great interest in the field of tumor biology and immunotherapy. Among the most promising approaches, phage display has been successfully used to select peptides and antibody fragments to a variety of different targets, including cancer cells, immune cells and cytokines. Peptides selected from phage display have been used to guide the delivery of lytic peptides, cytotoxic drugs, and nanoparticles to cancer cells with the aim to obtain more efficient and less toxic therapeutics. Addi- tionally, antibodies developed through phage display are being used in the treatment of autoimmune diseases and in some cases metastatic cancers. This review provides a short description of how phage libraries are designed, and highlights the conversion of the isolated binders into human therapeutics and use in targeted therapies. Keywords Phage display · Affinity selection · Peptides · Antibodies · Targeted therapies · Drug delivery · Immunotherapy · Biomarkers Abbreviations Introduction cDNA Complementary DNA CDR Complementarity-determining region Phage display is a molecular technique in which phage DNA EGF Epidermal growth factor is genetically modified to express on the phage surface a Fab Antigen-binding fragment peptide or protein fused to one of the phage coat proteins. FDA Food and drug administration This strategy is fundamentally different from other bacte- Ig Immunoglobulin rial expression systems in that the displayed peptides or mAb monoclonal antibody proteins and the DNA encoding them are physically linked.
    [Show full text]
  • INN Working Document 05.179 Update 2011
    INN Working Document 05.179 Update 2011 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) INN Working Document 05.179 Distr.: GENERAL ENGLISH ONLY 2011 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Essential Medicines and Pharmaceutical Policies (EMP) International Nonproprietary Names (INN) for biological and biotechnological substances (a review) © World Health Organization 2011 All rights reserved. Publications of the World Health Organization are available on the WHO web site (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; email: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press through the WHO web site (http://www.who.int/about/licensing/copyright_form/en/index.html). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned.
    [Show full text]
  • WHO Drug Information Vol 22, No
    WHO DRUG INFORMATION VOLUME 22 NUMBER 2 2008 PROPOSED INN LIST 99 INTERNATIONAL NONPROPRIETARY NAMES FOR PHARMACEUTICAL SUBSTANCES WORLD HEALTH ORGANIZATION GENEVA WHO Drug Information Vol 22, No. 2, 2008 World Health Organization WHO Drug Information Contents Access to Medicines Lapatinib and hepatoxicity 96 Telbivudine and peripheral neuropathy 96 WHO prequalification: progress in 2007 79 International Nonproprietary Safety and Efficacy Issues Names Update on safety of heparin 84 International Nonproprietary Names Nicorandil-associated ulceration 85 for monoclonal antibodies: IFPMA Topiramate and other drugs causing proposal 97 glaucoma 86 Varenicline: serious psychiatric reactions 86 Montelukast : safety review 88 Regulatory Action and News Neurocognitive effects of chemotherapy 89 Dydrogesterone withdrawn for New MMRV vaccine recommendations 89 commercial reasons 108 Oseltamivir label updated with neuro- Enoxaparin contamination: batches psychiatric warning 90 recalled 109 Ketoconazole tablets: risk of hepato- Recombinant antihemophilic factor toxicity 90 approved 110 Alemtuzumab: infection-related deaths 91 Rotavirus vaccine approved 111 Mycophenolate mofetil: progressive New version of genetically engineered multifocal leukoencephalopathy 91 Factor VIIa approved 111 Modafinil: serious rash and psychiatric symptoms 92 Moxifloxacin: serious hepatic and skin International Pharmacopoeia reactions 92 Role of The International Pharmacopoeia Rimonabant: depression; psychiatric in quality assurance 113 reactions 93 Exenatide: risk of acute
    [Show full text]